Anti-Androgen Receptor (phospho S650) antibody (ab47563)


  • Product nameAnti-Androgen Receptor (phospho S650) antibody
    See all Androgen Receptor primary antibodies
  • Description
    Rabbit polyclonal to Androgen Receptor (phospho S650)
  • SpecificityDetects endogenous levels of the Androgen Receptor only when phosphorylated at serine 650.
  • Tested applicationsSuitable for: IHC-P, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthesized phosphopeptide derived from the Human Androgen Receptor around the phosphorylation site of serine 650 (TTSPPT).

  • Positive control
    • Human prostate carcinoma tissue.


Associated products


Our Abpromise guarantee covers the use of ab47563 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
ELISA 1/20000.


  • FunctionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
    Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
  • Tissue specificityIsoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
  • Involvement in diseaseAndrogen insensitivity syndrome
    Spinal and bulbar muscular atrophy X-linked 1
    Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
    Androgen insensitivity, partial
  • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.
  • DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
  • Post-translational
    Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
    Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
  • Cellular localizationNucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
  • Information by UniProt
  • Database links
  • FormThere are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
  • Alternative names
    • AIS antibody
    • ANDR_HUMAN antibody
    • Androgen nuclear receptor variant 2 antibody
    • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
    • Androgen receptor antibody
    • androgen receptor splice variant 4b antibody
    • AR antibody
    • AR8 antibody
    • DHTR antibody
    • Dihydro testosterone receptor antibody
    • Dihydrotestosterone receptor (DHTR) antibody
    • Dihydrotestosterone receptor antibody
    • HUMARA antibody
    • HYSP1 antibody
    • KD antibody
    • Kennedy disease (KD) antibody
    • NR3C4 antibody
    • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
    • Nuclear receptor subfamily 3 group C member 4 antibody
    • SBMA antibody
    • SMAX1 antibody
    • Spinal and bulbar muscular atrophy (SBMA) antibody
    • Spinal and bulbar muscular atrophy antibody
    • Testicular Feminization (TFM) antibody
    • TFM antibody
    see all

Anti-Androgen Receptor (phospho S650) antibody images

  • ab47563, at 1/50 dilution, staining Androgen Receptor in Human prostate carcinoma by Immunohistochemistry, paraffin-embedded tissue. Left panel: no peptide; right panel: 1ug/ul blocking phosphopeptide.

References for Anti-Androgen Receptor (phospho S650) antibody (ab47563)

This product has been referenced in:
  • Yu HM  et al. eNOS-JNK1-AR signaling pathway mediates deltamethrin-induced germ cells apoptosis in testes of adult rats. Environ Toxicol Pharmacol 38:733-741 (2014). Read more (PubMed: 25299849) »
  • Narayanan R  et al. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res 70:842-51 (2010). WB ; Human . Read more (PubMed: 20068182) »

See all 4 Publications for this product

Product Wall

I am very pleased to hear you would like to accept our offer and test ab47563 in western blotting. This code will give you one free primary antibody before the expiration date. To redeem this offer, please submit an Abreview for western blotting and in...

Read More

Thank you for your call today and for letting us know about the trouble with this antibody.
Your credit note ID is ***. The purchase price will be refunded back to your credit card pending approval of our accounting department.
Our accounting...

Read More

We are happy to reassure our customers that all of our products are covered by our Abpromise, which guarantees that the product will work in the applications and species specified on the datasheet, or we will offer a replacement, credit, or refund with...

Read More